GLPwatch

Safety and Effectiveness of Tirzepatide Use in Obesity Without Type 2 Diabetes Mellitus.

Cureus · 2024

Last updated 2026-06-22
JournalCureus, 2024
Citations3
Relative citation ratio0.54
NIH percentile31
Molecules tirzepatide

Abstract

The challenge of obesity persists globally, requiring effective and safe treatment solutions. This literature review investigates the safety and effectiveness of tirzepatide, a new therapeutic agent, in managing obesity in patients who do not have type 2 diabetes mellitus (T2DM). A thorough search through electronic databases resulted in 25 relevant studies, among which 10 met the inclusion criteria. The results consistently demonstrate that tirzepatide for obese individuals without T2DM leads to significant weight loss, improved metabolic parameters, and better cardiovascular health. Adverse effects were generally mild and temporary, with gastrointestinal disturbances being the most frequent problem experienced by participants. These findings indicate the potential for adopting tirzepatide as a therapy option for non-diabetic individuals with obesity. However, further long-term research is necessary to determine its sustained efficacy and remain secure over time.

Verbatim abstract via PubMed 38322055 ↗

Related research